Abstracts tagged "gout and safety"

Abstract Number: 873 • 2018 ACR/ARHP Annual Meeting
General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Kenneth Saag¹, Michael A. Becker², William B. White³, Andrew Whelton⁴, Jeffrey Borer⁵, Philip Gorelick⁶, Barbara Hunt⁷, Majin Castillo⁷ and Lhanoo Gunawardhana⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago Pritzker School of Medicine, Chicago, IL, ³Cardiology, University of Connecticut School of Medicine, Farmington, CT, ⁴Johns Hopkins University School of Medicine, Hunt Valley, MD, ⁵State University of New York Downstate Medical Center, Brooklyn, NY, ⁶Michigan State University College of Human Medicine, Grand Rapids, MI, ⁷Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The cardiovascular (CV) safety study CARES has the longest study duration of any randomized controlled trial in patients (pts) with gout and CV disease.…
Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study
Seoyoung C. Kim¹, Tuhina Neogi², Eun Ha Kang³, Jun Liu⁴, Rishi J. Desai⁵, MaryAnn Zhang⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…
Abstract Number: 200 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Benzbromarone in Gout in Aotearoa New Zealand
Lisa K. Stamp¹, Janine Haslett¹, Christopher Frampton¹, Doug White², David Gardner³, Simon Stebbings⁴, Guy Taylor⁵, Rebecca Grainger⁶, Rajesh Kumar⁷, Sunil Kumar⁸, Tracey Kain⁹, David Porter¹⁰, Michael Corkill¹¹, Angela Cathro¹², Scott Metcalfe¹², John Wyeth¹² and Nicola Dalbeth¹³, ¹University of Otago, Christchurch, New Zealand, ²Waikato Hospital, Hamilton, New Zealand, ³Hawkes Bay DHB, Napier, New Zealand, ⁴Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, ⁵Whanganui Hospital, Whanganui, New Zealand, ⁶Wellington Regional Rheumatology Unit, Hutt Valley District Health Board, Lower Hutt, New Zealand, ⁷Taranaki Hospital, New Plymouth, New Zealand, ⁸Middlemore Hospital, Auckland, New Zealand, ⁹Tauranga Hospital, Tauranga Hospital, Tauranga, New Zealand, ¹⁰Porter Rheumatology Ltd, The Collingwood Centre, Nelson, New Zealand, ¹¹North Shore Hospital, Auckland, New Zealand, ¹²Pharmaceutical Management Agency, Wellington, New Zealand, ¹³Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Benzbromarone is a potent uricosuric, but is not widely available due to concerns about hepatotoxicity. In Aotearoa New Zealand benzbromarone has been available since…
Abstract Number: 2110 • 2015 ACR/ARHP Annual Meeting
Imaging and Safety Assessments Following Treatment with Febuxostat and Placebo for 2 Years in Subjects with Early Gout
Nicola Dalbeth¹, Kenneth G. Saag², William Palmer³, Hyon Choi³, Barbara Hunt⁴, Patricia MacDonald⁴, Ulrich Thienel⁴ and Lhanoo Gunawardhana⁴, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: No clinical trials had previously investigated the characteristics of joint damage in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…
Abstract Number: 1808 • 2014 ACR/ARHP Annual Meeting
Role of HLA-B*5801 Genetic Testing and a Safety Programme When Initiating Allopurinol Therapy for Chronic Gout Management: A Cost-Effectiveness Analysis
Di Dong¹, Wei Chuen Tan-Koi^2,3, Gim Gee Teng^4,5, Eric Finkelstein⁶ and Cynthia Sung^7,8, ¹Health Services and Systems Research Program, Duke-NUS Graduate Medical School, Singapore, Singapore, ²Vigilance & Compliance Branch, Health Sciences Authority, Singapore, Singapore, Singapore, ³Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁴Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁵Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, ⁶Health Services and Systems Research Program, Duke-NUS Graduate Medical School, Singapore., Singapore, Singapore, ⁷Vigilance & Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore, Singapore, Singapore, ⁸Emerging Infectious Diseases Program, Duke-NUS Graduate Medical School, Singapore., Singapore, Singapore
Background/Purpose To conduct a cost-effectiveness analysis from a health system perspective of various strategies in managing chronic gout to mitigate risk of allopurinol-induced Stevens-Johnson Syndrome…
Abstract Number: 164 • 2014 ACR/ARHP Annual Meeting
Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat
Thomas Bardin¹, René-Marc Flipo², Pascal Richette³ and Pierre Clerson⁴, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²rheumatology, Rene Salengro hospital, Lille, France, ³INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France, ⁴Orgametrie, Roubaix, France
Background/Purpose Allopurinol is the standard drug for urate-lowering management of gout. Allopurinol is safe in most patients. The most frequent side effects are minor cutaneous…
Abstract Number: 159 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Naomi Schlesinger¹, Rieke Alten², Thomas Bardin³, H. Ralph Schumacher Jr.⁴, Mark Bloch⁵, Karine Lheritier⁶, Dominik Richard⁶, Andrea Stancati⁷ and Alexander So⁸, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Charité University Medicine, Berlin, Germany, ³Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ⁴University of Pennsylvania VA Medical Center, Philadelphia, PA, ⁵Holdsworth House Medical Practice, Sydney, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Campus Forum 1, Novartis Pharma AG, Basel, Switzerland, ⁸Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
Background/Purpose Frequently flaring acute gouty arthritis (GA) patients (pts), in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective, need effective alternative treatments.1 Canakinumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].